Pemetrexed and carboplatin chemotherapy combined with whole brain radiotherapy for non-small cell lung cancer with brain metastasis

[1]  Meihua Wang,et al.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. , 2013, International journal of radiation oncology, biology, physics.

[2]  J. Régis,et al.  Stratégies de prise en charge des métastases cérébrales des malades atteints de cancers bronchiques primitifs , 2013 .

[3]  Jean Régis,et al.  [Management of brain metastases for lung cancer patients]. , 2013, Bulletin du cancer.

[4]  C. Ménard,et al.  A multi-institutional study of factors influencing the use of stereotactic radiosurgery for brain metastases. , 2013, International journal of radiation oncology, biology, physics.

[5]  P. Lambin,et al.  Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  D. Galetta,et al.  Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). , 2011, Lung cancer.

[7]  E. Smit,et al.  Time for reappraisal of extracranial treatment options? , 2011, Cancer.

[8]  G. Bepler,et al.  Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  S. Kaasa,et al.  Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Feng Gao,et al.  A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors , 2004, Clinical Cancer Research.

[13]  E. Eisenhauer,et al.  Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma , 2001, Cancer.